Biocon’s contract research arm -- Syngene International -- has expanded its ongoing drug discovery and development with US-based Bristol-Myers Squibb till 2026. The expanded scope of partnership also includes addition of a new facility and ramping up the team of scientists working for it. The next phase of the partnership will see the addition of a new facility to support future Bristol-Myers Squibb research and development operations.
As part of the expansion, Syngene will set up a new dedicated facility spread across 25,000 sq ft of laboratory and office space for Bristol-Myers Squibb. This facility will house an additional team of 75 Syngene scientists who will work exclusively for Bristol-Myers Squibb.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1863.90 |
| Dr. Reddys Lab | 1279.75 |
| Cipla | 1338.65 |
| Zydus Lifesciences | 935.55 |
| Lupin | 2250.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: